Literature DB >> 30268398

Kawasaki Disease Outcomes and Response to Therapy in a Multiethnic Community: A 10-Year Experience.

Shannon M Skochko1, Sonia Jain2, Xiaoying Sun2, Nipha Sivilay3, John T Kanegaye4, Joan Pancheri1, Chisato Shimizu3, Robert Sheets4, Adriana H Tremoulet4, Jane C Burns5.   

Abstract

OBJECTIVES: To describe the epidemiology, response to therapy, and outcomes of Kawasaki disease in a multiethnic community with a large Hispanic and Asian population. STUDY
DESIGN: We analyzed prospectively collected data from 788 unselected patients with Kawasaki disease diagnosed and treated at a single medical center over a 10-year period.
RESULTS: The average incidence of Kawasaki disease in children <5 years in San Diego County over the 10 years from 2006 to 2015 was 25 per 100 000 children, with the greatest incidence (50 per 100 000) for Asian/Pacific Islanders. Compared with other race/ethnicities, Asian/Pacific Islander patients with Kawasaki disease were younger, were diagnosed earlier in the course of their fever, had higher levels of inflammatory markers, and were more likely to develop aneurysms. There was no difference across race/ethnicity groups in response to intravenous immunoglobulin therapy. Filipino children had the highest recurrence rates (9.1%; 95% CI, 3.0%-22.6%) and 12 of 788 patients (1.5%) had a first- or second-degree relative with a history of Kawasaki disease. After correcting for age of onset, sex, and illness day at diagnosis, Asian/Pacific Islander children had an increased risk of developing aneurysms (aOR, 2.37; 95% CI, 1.37-4.11; P  = .002). Overall, 180 of 788 patients (22.8%) had a maximal Z score of 2.5-10.0 and 14 of the 788 patients (1.8%) had a maximal Z score ≥10.0 despite 84% of these patients being treated within 10 days of fever onset.
CONCLUSIONS: Our data provide new insights into the natural history of treated Kawasaki disease in a multiethnic population. Patient race/ethnicity influenced susceptibility to Kawasaki disease, timing of diagnosis, coronary artery outcome, and recurrence rates.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Kawasaki disease; coronary artery aneurysm; epidemiology; infliximab; intravenous immunoglobulin

Mesh:

Substances:

Year:  2018        PMID: 30268398     DOI: 10.1016/j.jpeds.2018.07.090

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  20 in total

1.  Phase I/IIa Trial of Atorvastatin in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysm.

Authors:  Adriana H Tremoulet; Sonia Jain; Pei-Ni Jone; Brookie M Best; Elizabeth H Duxbury; Alessandra Franco; Beth Printz; Samuel R Dominguez; Heather Heizer; Marsha S Anderson; Mary P Glodé; Feng He; Robert L Padilla; Chisato Shimizu; Emelia Bainto; Joan Pancheri; Harvey J Cohen; John C Whitin; Jane C Burns
Journal:  J Pediatr       Date:  2019-09-24       Impact factor: 4.406

2.  Etanercept With IVIg for Acute Kawasaki Disease: A Randomized Controlled Trial.

Authors:  Michael A Portman; Nagib S Dahdah; April Slee; Aaron K Olson; Nadine F Choueiter; Brian D Soriano; Sujatha Buddhe; Carolyn A Altman
Journal:  Pediatrics       Date:  2019-05-02       Impact factor: 7.124

3.  Evaluating the time-varying risk of hypertension, cardiac events, and mortality following Kawasaki disease diagnosis.

Authors:  Jennifer J Y Lee; Brian M Feldman; Brian W McCrindle; Ping Li; Rae Sm Yeung; Jessica Widdifield
Journal:  Pediatr Res       Date:  2022-08-24       Impact factor: 3.953

4.  NLRP3 Inflammasome Mediates Immune-Stromal Interactions in Vasculitis.

Authors:  Rebecca A Porritt; David Zemmour; Masanori Abe; Moshe Arditi; Magali Noval Rivas; Youngho Lee; Meena Narayanan; Thacyana T Carvalho; Angela C Gomez; Daisy Martinon; Chintda Santiskulvong; Michael C Fishbein; Shuang Chen; Timothy R Crother; Kenichi Shimada
Journal:  Circ Res       Date:  2021-09-14       Impact factor: 23.213

Review 5.  Kawasaki disease: pathophysiology and insights from mouse models.

Authors:  Magali Noval Rivas; Moshe Arditi
Journal:  Nat Rev Rheumatol       Date:  2020-05-26       Impact factor: 20.543

6.  Kawasaki Disease Patient Stratification and Pathway Analysis Based on Host Transcriptomic and Proteomic Profiles.

Authors:  Heather Jackson; Stephanie Menikou; Shea Hamilton; Andrew McArdle; Chisato Shimizu; Rachel Galassini; Honglei Huang; Jihoon Kim; Adriana Tremoulet; Adam Thorne; Roman Fischer; Marien I de Jonge; Taco Kuijpers; Victoria Wright; Jane C Burns; Climent Casals-Pascual; Jethro Herberg; Mike Levin; Myrsini Kaforou
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

7.  Severe refractory Kawasaki disease in seven infants in the COVID-19 era.

Authors:  Stefania Vergnano; Nele Alders; Catherine Armstrong; Andrew R Bamber; Srini Bandi; Jennifer A Evans; Nadia Hajiani; Julia Kenny; Filip Kucera; Andrew Tometzki; Orhan Uzun; Nick Wilkinson; Athimalaipet V Ramanan
Journal:  Lancet Rheumatol       Date:  2020-07-10

8.  Usefulness of Kawasaki disease risk scoring systems to the Turkish population.

Authors:  Kazım Öztarhan; Yusuf Ziya Varlı; Nuray Aktay Ayaz
Journal:  Anatol J Cardiol       Date:  2020-08       Impact factor: 1.596

9.  FNDC1 Polymorphism (rs3003174 C > T) Increased the Incidence of Coronary Artery Aneurysm in Patients with Kawasaki Disease in a Southern Chinese Population.

Authors:  Kun Lin; Linyuan Zhang; Yishuai Wang; Jinqing Li; Yufen Xu; Di Che; Hanran Mai; Hongyan Yu; Lanyan Fu; Bing Wei; Zhiyong Jiang; Lei Pi; Xiaoqiong Gu
Journal:  J Inflamm Res       Date:  2021-06-21

10.  Factors affecting the duration of coronary artery lesions in patients with the Kawasaki disease: a retrospective cohort study.

Authors:  Xuting Zhang; Yuee He; Yiping Shao; Biyao Hang; Zhipeng Xu; Maoping Chu
Journal:  Pediatr Rheumatol Online J       Date:  2021-06-26       Impact factor: 3.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.